New data a boost for Johnson & Johnson and Bavarian Nordic's Ebola vaccine
The Lancet has published new data on Johnson & Johnson and Bavarian Nordic's combined vaccine against Ebola, which according to the US life science group strongly supports preventatitve use of the vaccine.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY CATHERINE BRETT
Results from two new studies that have recently been published by medical journal The Lancet are a cause for celebration at Johnson & Johnson.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Bavarian Nordic to supply UK with monkeypox vaccines
For subscribers
